ASCO Genitourinary Cancers Symposium approaches, several highly anticipated studies are set to shape the future of treatment ...

For patients undergoing prostate radiotherapy, acute toxicity is associated with late toxicity and decrement in qua ...

First real-world outcomes data for ADSTILADRIN® (nadofaragene firadenovec-vncg) to be presented at 2025 ASCO Genitourinary ...

Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) ...

Flatiron Health today announced its planned presence at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), including ...

Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...

At the European Society for Medical Oncology (ESMO) 2024, renowned experts, Michael Jewett, Andrea Necchi and Laurence Albiges discuss ...

Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, announced today ...